Zomedica Corp. (NYSEAMERICAN:ZOM - Get Free Report) Director Johnny D. Powers acquired 100,000 shares of the business's stock in a transaction dated Wednesday, August 28th. The shares were acquired at an average cost of $0.13 per share, with a total value of $13,000.00. Following the transaction, the director now owns 2,325,000 shares in the company, valued at $302,250. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Zomedica Price Performance
NYSEAMERICAN:ZOM remained flat at $0.13 during mid-day trading on Wednesday. The company's stock had a trading volume of 3,493,901 shares, compared to its average volume of 4,885,456. The company has a market capitalization of $123.57 million, a price-to-earnings ratio of -3.15 and a beta of 0.97. Zomedica Corp. has a twelve month low of $0.12 and a twelve month high of $0.23.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in ZOM. Virtu Financial LLC boosted its holdings in Zomedica by 1,585.0% in the 1st quarter. Virtu Financial LLC now owns 168,773 shares of the company's stock worth $25,000 after buying an additional 158,757 shares during the period. Frazier Financial Advisors LLC bought a new position in shares of Zomedica in the fourth quarter worth about $50,000. Finally, Price T Rowe Associates Inc. MD raised its stake in Zomedica by 41.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 948,300 shares of the company's stock valued at $139,000 after purchasing an additional 276,100 shares during the period. 8.95% of the stock is currently owned by institutional investors.
Zomedica Company Profile
(
Get Free Report)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zomedica wasn't on the list.
While Zomedica currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
